162 related articles for article (PubMed ID: 19689407)
1. Pharmacological options for treatment of hyperandrogenic disorders.
Reismann P; Likó I; Igaz P; Patócs A; Rácz K
Mini Rev Med Chem; 2009 Aug; 9(9):1113-26. PubMed ID: 19689407
[TBL] [Abstract][Full Text] [Related]
2. Anti-androgens for the treatment of hirsutism.
Carmina E
Expert Opin Investig Drugs; 2002 Mar; 11(3):357-63. PubMed ID: 11866665
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the chemistry and pharmacological activity of new steroidal antiandrogens and 5 alpha-reductase inhibitors.
Bratoeff E; Cabeza M; Ramirez E; Heuze Y; Flores E
Curr Med Chem; 2005; 12(8):927-43. PubMed ID: 15853706
[TBL] [Abstract][Full Text] [Related]
4. Steroidal antiandrogens and 5alpha-reductase inhibitors.
Bratoeff E; Ramírez E; Murillo E; Flores G; Cabeza M
Curr Med Chem; 1999 Dec; 6(12):1107-23. PubMed ID: 10519917
[TBL] [Abstract][Full Text] [Related]
5. Management of hirsutism.
Falsetti L; Gambera A; Platto C; Legrenzi L
Am J Clin Dermatol; 2000; 1(2):89-99. PubMed ID: 11702316
[TBL] [Abstract][Full Text] [Related]
6. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.
Moghetti P; Tosi F; Castello R; Magnani CM; Negri C; Brun E; Furlani L; Caputo M; Muggeo M
J Clin Endocrinol Metab; 1996 Mar; 81(3):952-60. PubMed ID: 8772557
[TBL] [Abstract][Full Text] [Related]
7. Hormonal therapies in acne.
Shaw JC
Expert Opin Pharmacother; 2002 Jul; 3(7):865-74. PubMed ID: 12083987
[TBL] [Abstract][Full Text] [Related]
8. Hirsutism - from diagnosis to use of antiandrogens.
Unluhizarci K; Karaca Z; Kelestimur F
Front Horm Res; 2013; 40():103-14. PubMed ID: 24002408
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of testosterone and dihydrotestosterone metabolism in women].
Korsić M
Lijec Vjesn; 1996 Mar; 118 Suppl 1():21-3. PubMed ID: 8759403
[TBL] [Abstract][Full Text] [Related]
10. [Antiandrogens. Mechanisms and paradoxical effects].
Mowszowicz I
Ann Endocrinol (Paris); 1989; 50(3):189-99. PubMed ID: 2530930
[TBL] [Abstract][Full Text] [Related]
11. Flutamide and cyproterone acetate exert agonist effects: induction of androgen receptor-dependent neuroprotection.
Nguyen TV; Yao M; Pike CJ
Endocrinology; 2007 Jun; 148(6):2936-43. PubMed ID: 17347309
[TBL] [Abstract][Full Text] [Related]
12. Acne: effect of hormones on pathogenesis and management.
Shaw JC
Am J Clin Dermatol; 2002; 3(8):571-8. PubMed ID: 12358558
[TBL] [Abstract][Full Text] [Related]
13. Targets to treat androgen excess in polycystic ovary syndrome.
Luque-Ramírez M; Escobar-Morreale HF
Expert Opin Ther Targets; 2015; 19(11):1545-60. PubMed ID: 26549181
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor antagonists (antiandrogens): structure-activity relationships.
Singh SM; Gauthier S; Labrie F
Curr Med Chem; 2000 Feb; 7(2):211-47. PubMed ID: 10637363
[TBL] [Abstract][Full Text] [Related]
15. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins.
Ayub M; Levell MJ
J Steroid Biochem; 1989 Aug; 33(2):251-5. PubMed ID: 2788775
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of 5alpha-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro.
Seiffert K; Seltmann H; Fritsch M; Zouboulis CC
Horm Metab Res; 2007 Feb; 39(2):141-8. PubMed ID: 17326010
[TBL] [Abstract][Full Text] [Related]
18. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
19. Antiandrogens in prostate cancer.
Reid P; Kantoff P; Oh W
Invest New Drugs; 1999; 17(3):271-84. PubMed ID: 10665479
[TBL] [Abstract][Full Text] [Related]
20. New 5alpha-reductase inhibitors: in vitro and in vivo effects.
Pérez-Ornelas V; Cabeza M; Bratoeff E; Heuze I; Sánchez M; Ramírez E; Naranjo-Rodríguez E
Steroids; 2005 Mar; 70(3):217-24. PubMed ID: 15763601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
